J&J emerged victorious in a patent suit claiming that the technology behind Abbott's blockbuster arthritis treatment Humira is too similar in design to J&J's Remicade. The cost to Abbott: $1.67 Billion.
Abbott Laboratories lost its battle against Johnson & Johnson on Monday, as a federal jury found the company guilty of patent infringement and levied a $1.67 billion in damages.
At issue was whether or not Abbott’s anti-tumor necrosis factor arthritis drug Humira infringed on J&J’s blockbuster Remicade, co-owned by New York University and marketed by J&J’s bio arm Centocor. Like Remicade, Humira is a fully human antibody, but the former drug once included some mouse-based components. Abbott claims that a fully human version did not exist when Humira was conceived; J&J didn’t deny the claim.
“J&J acknowledged at trial that it did not start working on a fully human antibody until 1997-two years after Abbott discovered Humira and one year after Abbott filed its patent applications for Humira,” stated Abbott spokesman Scott Stoffel in a press statement.
“We are pleased that the jury has ruled in our favor in the patent litigation case against Abbott,” said Kim Taylor, president, Centocor Ortho Biotech, in a release. “We are particularly gratified that the jury recognized our valuable intellectual property, finding our patent both valid and infringed. We will continue to assert intellectual property rights for our immunology therapies, as they offer significant advances in treatment for patients with a number of immune mediated inflammatory diseases.”
J&J currently shares overseas rights to Remicade with Schering-Plough. However, that deal got a bit squirrelly when Merck bought Schering earlier this year. The original deal called for controlling stakes in Remicade to revert to J&J if Schering was sold, but the reverse merger arrangement of the Merck/Schering deal managed to avert that scenario.
Merck and J&J are currently in arbitration to figure out that deal.
Reuters reports that Abbott is planning to appeal the verdict.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.